Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.
Adjei A, LoRusso P, Ribas A, Sosman J, Pavlick A, Dy G, Zhou X, Gangolli E, Walker R, Kneissl M, Faucette S, Neuwirth R, Bozon V. Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors. Journal Of Clinical Oncology 2013, 31: 2528-2528. DOI: 10.1200/jco.2013.31.15_suppl.2528.Peer-Reviewed Original ResearchAdvanced solid tumorsDrug-related AEsSolid tumorsAcneiform dermatitisTAK-733Creatine phosphokinase increaseECOG PS 0Oral MEK inhibitorDose-escalation studyDose-proportional mannerMean accumulation ratioPeripheral blood samplesAnti-tumor activitySteady-state exposurePower model analysisStable diseasePS 0Partial responseEvaluable tumorsPeripheral bloodPustular rashBlood samplesXenograft modelHuman studiesMaximal efficacy